Innova Captab LtdNSE:INNOVACAP
Current view Q4 2026
Medicine-maker's sales jumped 31%, led by fast-growing own brands. New Jammu factory barely used yet - big growth runway - but it keeps missing management's targets, and profit grew only 10%.
Latest exchange filings last 5 · 5 after Q4 2026
- 15 Sep ’26Innova Captab will attend Anand Rathi G-200 Summit 2026 on 21 September 2026 in Mumbai. ↗
- 5 Sep ’26Pursuant to the regulation 30 read with schedule III, Part A, Para A and regulation 47 of SEBI (LODR) Regulations, 2015 ("Listing regulations") .... ↗
- 5 Sep ’26Innova Captab schedules 22nd AGM on 30 September 2026; annual report 2025-26 and e-voting dates shared. ↗
- 4 Sep ’26Innova Captab submitted its BRSR for FY 2025-26, forming part of the Integrated Annual Report. ↗
- 4 Sep ’26Reg. 34 (1) Annual Report. 4 Sep ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +42.2% | −0.4% | +20.7% | +31.7% |
| Operating profit | ▲ +35.4% | −5.8% | +26.7% | +35.4% |
| EPS | ▲ +28.6% | −9.8% | +20.3% | −38.8% |
| PAT | ▲ +26.7% | −9.5% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is PAT at +26.7%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Average62/100
Growing fast — and the market has noticed. Profit per share grew 20% a year, and buyers now pay more for each rupee of it than they did a year ago. Some of the re-pricing has already happened.
₹1,271 → ₹2,542 needs the P/E at 59× — it is 52× today, and has ranged 37× to 78× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 89× — never traded above 78× in 5 years.
At ₹1,302 the price-tag on its earnings reaches the 53× it is being projected toward — the point where being cheap against that yardstick is used up.
Re-rated already, on growth that doesn't fully back it.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a small-cap at ₹6,479 cr, so the odds of a re-rate are not fighting its own size.
Growth rate used: 20.3% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 29%.
How it compares with its rivals Healthcare · 6 of 159 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Innova Captab | ₹1,166 | 43.4× | ₹6,675 Cr | 15.0% | +42.3% | +33.9% |
| Sun Pharma.Inds. | ₹1,851 | 35.1× | ₹4.44 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,377 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,855 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,154 | 23.7× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,375 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — a little wider than 3 years earlier | operating margin 13% → 16% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it, with some tied up | 59% last year, 73% over three · free cash flow ₹55 cr, positive in 1 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹344 cr — 0.32× its own equity (was 0.35×) |
| Is it being collected? | collection is steady | 98 days to collect, up 1 in a year · cash cycle 82 days |
| Who has been buying? | the promoters have held steady | promoters 50.9%, 50.9% → 50.9% over 2.5 years · FIIs 0.3% (+0.1) · DIIs 19.9% (+0.3) · shareholders 1,39,117 → 35,881 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 15.0% · ROE 13.7% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company is expected to give good quarter
- Company has delivered good profit growth of 32.5% CAGR over last 5 years
Against it
- Company might be capitalizing the interest cost
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.